Atlas Trials

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Clinical trial NCT01318434 · COMPLETED

Trial details

NCT number
NCT01318434
Sponsor
Euthymics BioScience, Inc.
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Major Depressive Disorder
Start date
2011-02-01
Primary completion
2013-02-01
Enrollment
342

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.